Paper41044643
LCP1 upregulation via EGFR signaling promotes oral cancer progression through the JAK2/STAT3/IL-1β axis.
Liu CR and 7 others. Cancer Cell Int, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. LCP1 upregulation via EGFR signaling promotes oral cancer progression through the JAK2/STAT3/IL-1β axis. Papers, record 41044643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41044643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- LCP1 upregulation via EGFR signaling promotes oral cancer progression through the JAK2/STAT3/IL-1β axis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 111-2314-B-182A-078-MY3 | National Science and Technology Council, Taiwan | PubMed | ||
| 113-2313-B-005-014 | National Science and Technology Council, Taiwan | PubMed | ||
| 112-2320-B-182-044 | National Science and Technology Council, Taiwan | PubMed | ||
| CMRPG3J1253 | Chang Gung Memorial Hospital, Taiwan | PubMed | ||
| BMRPC77 | Chang Gung Memorial Hospital, Taiwan | PubMed | ||
| NCHU-CCH11306 | National Chung Hsing University/Changhua Christian Hospital Joint Research Program | PubMed | ||
| NCHU-CCH11306 | National Chung Hsing University/Changhua Christian Hospital Joint Research Program | PubMed | ||
| NSTC 114-2320-B-182-025 | National Science and Technology Council | PubMed |
Source PubMed
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23362108 | Epigenetic regulation of the X-linked tumour suppressors BEX1 and LDOC1 in oral squamous cell carcinoma. | J Pathol | 2013 | https://conductscience.org/library/papers/23362108 | PubMed |
| 2 | 33739025 | An integrated approach for identification of a panel of candidate genes arbitrated for invasion and metastasis in oral squamous cell carcinoma. | Sci Rep | 2021 | https://conductscience.org/library/papers/33739025 | PubMed |
| 3 | 16636079 | Phosphorylation on Ser5 increases the F-actin-binding activity of L-plastin and promotes its targeting to sites of actin assembly in cells. | J Cell Sci | 2006 | https://conductscience.org/library/papers/16636079 | PubMed |
| 4 | 18645125 | Biological markers and prognosis in recurrent oral cancer after salvage surgery. | Arch Otolaryngol Head Neck Surg | 2008 | https://conductscience.org/library/papers/18645125 | PubMed |
| 5 | 10629546 | Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. | J Pathol | 1999 | https://conductscience.org/library/papers/10629546 | PubMed |
| 6 | 32610557 | Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32610557 | PubMed |
| 7 | 37501404 | Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer. | Mol Oncol | 2023 | https://conductscience.org/library/papers/37501404 | PubMed |
| 8 | 36209263 | Tumor microenvironment and immunotherapy of oral cancer. | Eur J Med Res | 2022 | https://conductscience.org/library/papers/36209263 | PubMed |
| 9 | 39780248 | Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. | Mol Cancer | 2025 | https://conductscience.org/library/papers/39780248 | PubMed |
| 10 | 26919428 | NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. | Cell | 2016 | https://conductscience.org/library/papers/26919428 | PubMed |
| 11 | 24555657 | Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. | Mol Cancer | 2014 | https://conductscience.org/library/papers/24555657 | PubMed |
| 12 | 38560690 | Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer. | Heliyon | 2024 | https://conductscience.org/library/papers/38560690 | PubMed |
| 13 | 31253657 | Identification of Salivary Biomarkers for Oral Cancer Detection with Untargeted and Targeted Quantitative Proteomics Approaches. | Mol Cell Proteomics | 2019 | https://conductscience.org/library/papers/31253657 | PubMed |
| 14 | 35048046 | IL-1/IL-1R Signaling in Head and Neck Cancer. | Front Oral Health | 2021 | https://conductscience.org/library/papers/35048046 | PubMed |
| 15 | 20169155 | Quantitative kinetic study of the actin-bundling protein L-plastin and of its impact on actin turn-over. | PLoS One | 2010 | https://conductscience.org/library/papers/20169155 | PubMed |
| 16 | 30409303 | Label-free tissue proteomics can classify oral squamous cell carcinoma from healthy tissue in a stage-specific manner. | Oral Oncol | 2018 | https://conductscience.org/library/papers/30409303 | PubMed |
| 17 | 22825581 | Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22825581 | PubMed |
| 18 | 25204733 | IL-1β promotes malignant transformation and tumor aggressiveness in oral cancer. | J Cell Physiol | 2015 | https://conductscience.org/library/papers/25204733 | PubMed |
| 19 | 19924637 | Nicotinamide N-Methyltransferase upregulation correlates with tumour differentiation in oral squamous cell carcinoma. | Histol Histopathol | 2010 | https://conductscience.org/library/papers/19924637 | PubMed |
| 20 | 37079976 | Tumour microenvironment and aberrant signaling pathways in cisplatin resistance and strategies to overcome in oral cancer. | Arch Oral Biol | 2023 | https://conductscience.org/library/papers/37079976 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| EGF | 1950 | PubTator's text mining | https://conductscience.org/library/genes/1950 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| IL1B | 3553 | PubTator's text mining | https://conductscience.org/library/genes/3553 | NCBI Gene |
| JAK2 | 3717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| LCP1 | 3936 | PubTator's text mining | https://conductscience.org/library/genes/3936 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
| STAT3 | 6774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41044643
GET https://conductscience.org/api/papers/v1/41044643/references?page=2